Form 4: Recursion Pharmaceuticals CFO Ben R. Taylor Reports Changes in Beneficial Ownership
SEC Form 4
Ben R. Taylor, CFO of Recursion Pharmaceuticals, filed a Form 4 disclosing changes in his beneficial ownership of company stock due to tax withholding related to restricted stock units.
Summary
- On May 15, 2025, Ben R. Taylor, the Chief Financial Officer of Recursion Pharmaceuticals, reported changes in his beneficial ownership of the company's stock.
- The filing indicates that 11,908 shares of Class A Common Stock were disposed of at a price of $4.25 per share to cover tax obligations related to the net settlement of restricted stock units.
- Following the transaction, Mr. Taylor directly owns 830,191 shares of Class A Common Stock.
- The filing also details Mr. Taylor's holdings of various stock options with different exercise prices and expiration dates.
Sentiment
Score: 5
Explanation: This is a neutral filing related to standard executive compensation practices. It doesn't indicate positive or negative performance, just routine transactions.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing is typical for executives receiving stock-based compensation.
Comparison to Industry Standards
- Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
- The vesting schedules and exercise prices of the stock options are within the typical range for similar companies in the biotechnology industry.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize stock-based compensation for their executives.
Stakeholder Impact
- The transaction has a minimal direct impact on shareholders, as it is related to tax obligations on existing equity compensation.
- The filing provides transparency to stakeholders regarding executive compensation and ownership.
Key Dates
| Date | Description |
|---|---|
| 11/17/2021 | 25% of shares subject to one stock option award vest and become exercisable, with the remaining shares vesting in annual installments thereafter. |
| 04/03/2022 | 25% of shares subject to one stock option award vest and become exercisable, with the remaining shares vesting in quarterly installments thereafter. |
| 07/01/2022 | 25% of shares subject to one stock option award vest and become exercisable, with the remaining shares vesting in quarterly installments thereafter. |
| 01/02/2025 | 1/48th of the shares subject to one stock option award vests and become exercisable, and each month thereafter. |
| 03/01/2025 | 1/48th of the shares subject to one stock option award vests and become exercisable, and each month thereafter. |
| 05/15/2025 | Date of transaction where shares were withheld to satisfy tax obligations. |
| 07/01/2031 | Expiration date of one stock option award. |
| 04/02/2031 | Expiration date of one stock option award. |
| 11/26/2030 | Expiration date of one stock option award. |
| 12/18/2034 | Expiration date of one stock option award. |
| 02/03/2035 | Expiration date of one stock option award. |
| 05/19/2025 | Date of filing. |
Keywords
Form 4, Beneficial Ownership, Recursion Pharmaceuticals, RXRX, Ben R. Taylor, CFO, Stock Options, Class A Common Stock, Tax Withholding, Restricted Stock Units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.